Navidea (NAVB) Appoints Anton Gueth To Board Of Directors

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces today the appointment of Mr. Anton Gueth to fill an open position on the Navidea Board of Directors. Mr. Gueth's initial term of service will last until the Company's 2016 Annual Meeting at which time he is expected to stand for re-election. Mr. Gueth brings over 30 years of global finance and operating experience in the pharmaceutical and healthcare industries.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.